Prostate cancer germline variants with therapeutic implications

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Prostate cancer is a highly heritable malignancy with significant mortality.
• Germline alterations in DNA repair and androgen synthesis genes correlate with adverse outcomes.
• Prevalent pathogenic variants include BRCA1, BRCA2, and HSD3B1, impacting disease risk and progression.

Purpose of the Study:

• To review the impact of pathogenic germline alterations in prostate cancer.
• To focus on common and clinically actionable genetic variants.
• To highlight therapeutic implications of these genetic findings.

Main Methods:

• Literature review of studies on prostate cancer genetics.
• Analysis of germline alterations in DNA repair and androgen synthesis pathways.
• Examination of clinical data on variant prevalence and treatment response.

Main Results:

• BRCA1, BRCA2, and HSD3B1 are the most common pathogenic germline alterations in advanced prostate cancer.
• These variants are associated with increased risk and progression of prostate cancer.
• Pharmacological targeting of these variants shows promise.

Conclusions:

• Germline variants in BRCA1/2 and HSD3B1 are critical in prostate cancer development and progression.
• PARP inhibitors offer survival benefits for BRCA1/2 mutation carriers.
• HSD3B1 variants may benefit from intensified androgen blockade.